Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3 ; volume:13 ; number:1 ; day:17 ; month:8 ; year:2023 ; pages:1-15 ; date:12.2023
Scientific reports ; 13, Heft 1 (17.8.2023), 1-15, 12.2023
- Urheber
-
Rampuria, Pragya
Mosyak, Lidia
Root, Adam R.
Svenson, Kristine
Agostino, Michael J.
LaVallie, Edward R.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-40467-0
- URN
-
urn:nbn:de:101:1-2024020613234546389229
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rampuria, Pragya
- Mosyak, Lidia
- Root, Adam R.
- Svenson, Kristine
- Agostino, Michael J.
- LaVallie, Edward R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy